GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Cytophage Technologies (TSXV:CYTO) Cash, Cash Equivalents, Marketable Securities : C$1.52 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Cash, Cash Equivalents, Marketable Securities?

Cytophage Technologies's quarterly cash, cash equivalents, marketable securities declined from Jun. 2024 (C$3.66 Mil) to Sep. 2024 (C$2.35 Mil) but then stayed the same from Sep. 2024 (C$2.35 Mil) to Dec. 2024 (C$1.52 Mil).

Cytophage Technologies's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (C$2.25 Mil) to Dec. 2023 (C$0.03 Mil) but then increased from Dec. 2023 (C$0.03 Mil) to Dec. 2024 (C$1.52 Mil).


Cytophage Technologies Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Cytophage Technologies's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Cash, Cash Equivalents, Marketable Securities Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
4.84 2.25 0.03 1.52

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.03 5.57 3.66 2.35 1.52

Cytophage Technologies Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Cytophage Technologies  (TSXV:CYTO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Cytophage Technologies Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
200A - 400 Fort Whyte Way, Oak Bluff, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics.

Cytophage Technologies Headlines

No Headlines